在IgA瘤患者中,诺华的Fabhalta可减缓功能衰退. Novartis' Fabhalta slows kidney function decline in IgA nephropathy patients.

诺华公司宣布其制药Fabhalta显著减缓了IgA脏病患者的功能衰退. Novartis announced that its drug Fabhalta significantly slowed kidney function decline in patients with IgA nephropathy. 功能改善49. 3%,衰竭风险降低43%,同时保持了良好的安全性. The study showed a 49.3% improvement in kidney function and a 43% reduction in kidney failure risk, while maintaining a favorable safety profile. 美国食品和药物管理局已经批准该药物的优先审查. The U.S. FDA has granted priority review for the drug's approval.